Ilyang Pharmaceutical company completed patient enrollment in Phase III clinical trial of Suepect

Published: 2014-02-28 15:29:47

Updated: 2014-02-28 15:29:47

On Feb 26, Ilyang Pharmaceutical company (CEO Kim, Dong-Youn) announced that they has completed patient enrollment in Phase III clinical trials of leukemia treatment 'Supect (ingredient: radotinib)' for its entry into the first line treatment.

'Supect' has proceeded with Phase III clinical trials from last August 2011 in Korea Seoul St. Mary's Hospital. It has completed patient enrollment in...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.